Literature DB >> 20711227

Therapeutic implications of chemokine-mediated pathways in atherosclerosis: realistic perspectives and utopias.

Stavros Apostolakis1, Virginia Amanatidou, Demetrios A Spandidos.   

Abstract

Current perspectives on the pathogenesis of atherosclerosis strongly support the involvement of inflammatory mediators in the establishment and progression of atherosclerostic lesions. Chemokine-mediated mechanisms are potent regulators of such processes by orchestrating the interactions of inflammatory cellular components of the peripheral blood with cellular components of the arterial wall. The increasing evidence supporting the role of chemokine pathways in atherosclerosis renders chemokine ligands and their receptors potential therapeutic targets. In the following review, we aim to highlight the special structural and functional features of chemokines and their receptors in respect to their roles in atherosclerosis, and examine to what extent available data can be applied in disease management practices.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20711227      PMCID: PMC4002307          DOI: 10.1038/aps.2010.131

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  64 in total

1.  Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets.

Authors:  Christian Schulz; Andreas Schäfer; Moritz Stolla; Sandra Kerstan; Michael Lorenz; Marie-Luise von Brühl; Matthias Schiemann; Johann Bauersachs; Torsten Gloe; Dirk H Busch; Meinrad Gawaz; Steffen Massberg
Journal:  Circulation       Date:  2007-08-06       Impact factor: 29.690

Review 2.  Platelets as immune cells: bridging inflammation and cardiovascular disease.

Authors:  Philipp von Hundelshausen; Christian Weber
Journal:  Circ Res       Date:  2007-01-05       Impact factor: 17.367

Review 3.  Chemokine regulation of atherosclerosis.

Authors:  Jana Barlic; Philip M Murphy
Journal:  J Leukoc Biol       Date:  2007-03-29       Impact factor: 4.962

Review 4.  Chemokines in vascular pathology (review).

Authors:  Stavros Apostolakis; Emmanouil G Papadakis; Elias Krambovitis; Demetrios A Spandidos
Journal:  Int J Mol Med       Date:  2006-05       Impact factor: 4.101

5.  Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment.

Authors:  Christian Weber; Sandra Kraemer; Maik Drechsler; Hongqi Lue; Rory R Koenen; Aphrodite Kapurniotu; Alma Zernecke; Jürgen Bernhagen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

6.  Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis.

Authors:  Noah Saederup; Liana Chan; Sergio A Lira; Israel F Charo
Journal:  Circulation       Date:  2007-12-28       Impact factor: 29.690

7.  Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial.

Authors:  Clarissa E Vergunst; Daniëlle M Gerlag; Luba Lopatinskaya; L Klareskog; M D Smith; F van den Bosch; Huib J Dinant; Yih Lee; Timothy Wyant; Eric W Jacobson; Dominique Baeten; Paul P Tak
Journal:  Arthritis Rheum       Date:  2008-07

8.  Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial.

Authors:  James A de Lemos; David A Morrow; Michael A Blazing; Petr Jarolim; Stephen D Wiviott; Marc S Sabatine; Robert M Califf; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2007-11-13       Impact factor: 24.094

9.  Fractalkine upregulates intercellular adhesion molecule-1 in endothelial cells through CX3CR1 and the Jak Stat5 pathway.

Authors:  Xiao Ping Yang; Subhendra Mattagajasingh; Shaobo Su; Guibin Chen; Zheqing Cai; Karen Fox-Talbot; Kaikobad Irani; Lewis C Becker
Journal:  Circ Res       Date:  2007-09-20       Impact factor: 17.367

10.  CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of pre-inflammatory stimuli and renin-angiotensin system modulators.

Authors:  Stavros Apostolakis; Elias Krambovitis; Zaharenia Vlata; Georgios E Kochiadakis; Stavroula Baritaki; Demetrios A Spandidos
Journal:  Thromb Res       Date:  2007-05-23       Impact factor: 3.944

View more
  6 in total

1.  Leukocyte chemoattractant receptor FPR2 may accelerate atherogenesis.

Authors:  Wuzhou Wan; Ji-Liang Gao
Journal:  Med Hypotheses       Date:  2012-04-26       Impact factor: 1.538

Review 2.  The Role of CXC Chemokines in Cardiovascular Diseases.

Authors:  Xiyi Lu; Zhen Wang; Di Ye; Yongqi Feng; Menglin Liu; Yao Xu; Menglong Wang; Jishou Zhang; Jianfang Liu; Mengmeng Zhao; Shuwan Xu; Jing Ye; Jun Wan
Journal:  Front Pharmacol       Date:  2022-05-20       Impact factor: 5.988

Review 3.  Chemokines and atherosclerosis: focus on the CX3CL1/CX3CR1 pathway.

Authors:  Stavros Apostolakis; Demetrios Spandidos
Journal:  Acta Pharmacol Sin       Date:  2013-08-26       Impact factor: 6.150

Review 4.  Chemokines and Their Receptors Are Key Players in the Orchestra That Regulates Wound Healing.

Authors:  Manuela Martins-Green; Melissa Petreaca; Lei Wang
Journal:  Adv Wound Care (New Rochelle)       Date:  2013-09       Impact factor: 4.730

5.  The Interaction between Fluid Wall Shear Stress and Solid Circumferential Strain Affects Endothelial Gene Expression.

Authors:  Ronny Amaya; Alexis Pierides; John M Tarbell
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

6.  Lipoprotein redox status evaluation as a marker of cardiovascular disease risk in patients with inflammatory disease.

Authors:  Anca Ungurianu; Denisa Margină; Daniela Grădinaru; Claudia Băcanu; Mihaela Ilie; Christina Tsitsimpikou; Konstantinos Tsarouhas; Demetrios A Spandidos; Aristides M Tsatsakis
Journal:  Mol Med Rep       Date:  2016-11-28       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.